Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy
HER2-positive breast cancer is a unique subtype of the disease, not only in terms of aggressive biology, but also in terms of treatment options. Over the past 15 years, the strategy for treating early HER2-positive breast cancer has undergone a real evolution – from the absence of anti-HER2 therapy...
Main Authors: | I. V. Kolyadina, I. V. Poddubnaya |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2021-01-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/766 |
Similar Items
-
Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01) -
Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01) -
HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01) -
Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii
by: Irina Vladimirovna Kolyadina, et al.
Published: (2013-09-01) -
Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)